logo

For the Inventor, By the Inventor

Wiesbaden, Germany

Reinhard Becker

This inventor holds 28 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignee: Hoechst Aktiengesellschaft. Active years: 1985-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reinhard Becker. Retrieved from https://idiyas.com/inventor/reinhard-becker-8qhdqj63

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 28

% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 12

Forward Citations = 275(Granted Patents)


Company Filing History:

goldMedal28 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents

Years Active: 1985-1998

Loading Chart...
Areas of Expertise:
Angiotensin-Converting Enzyme Inhibitors
Amino Acid Derivatives
Pharmaceutical Composition
Hypertension Treatment
Bicyclic Aminoacids
Azole Derivatives
Spirocyclic Aminoacid Derivatives
Intermediates
Tricyclic Aminoacids
Fused Azepinone
Medicaments
Preparation Processes
28 patents (USPTO):Explore Patents
1. 5721244 - Combination of angiotensin-converting enzyme inhibitors with calcium (1998-02-24),
2. 5604251 - Imidazole derivatives with a biphenylsulfonylurea or (1997-02-18),
3. 5500434 - Combination of angiotensin-converting enzyme inhibitors with calcium (1996-03-19),
4. 5482957 - Azole derivatives, process for their preparation and their use (1996-01-09),
5. 5366994 - Use of a combination of angiotensin-converting enzyme inhibitor and (1994-11-22),
6. 5256687 - Pharmaceutical composition for the treatment of high blood pressure (1993-10-26),
7. 5236933 - Use of a combination of angiotensin-converting enzyme inhibitor and (1993-08-17),
8. 5114962 - New amino acid esters, a process for their preparation, medicaments (1992-05-19),
9. 5101039 - Azabicycloamino carboxylic acid intermediates (1992-03-31),
10. 5098910 - Combination of angiotensin-converting enzyme inhibitors with calcium (1992-03-24),
11. 5061722 - Cis, endo-2-azabicyclo-[3.3.0]-octane-3-carboxylic acids, a process for (1991-10-29),
12. 5055483 - Novel amino acid glycerides, learning medicaments containing them and (1991-10-08),
13. 5053519 - Cis, endo-2-azabicyclo-[3.3.0]-octane-5-carboxylic acids (1991-10-01),
14. 5008400 - Bicyclic aminoacids as intermediates (1991-04-16),
15. 4975453 - Combination of angiotensin converting enzyme inhibitors with potassium (1990-12-04),

Title: Reinhard Becker: Innovator in Medicinal Chemistry

Introduction: Reinhard Becker, based in Wiesbaden, Germany, is a prominent inventor with an impressive portfolio of 28 patents. His contributions to the field of medicinal chemistry have had significant impact, particularly in the development of novel pharmaceutical compounds.

Latest Patents: Among his latest innovations, Becker has developed a patent for the combination of angiotensin-converting enzyme inhibitors with calcium antagonists. This invention outlines the effective processes for their preparation and their utilization as medicaments. Additionally, he has worked on imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, detailing processes for their preparation and potential applications in therapy.

Career Highlights: Reinhard Becker has established himself as a valuable asset in the pharmaceutical industry, primarily through his work with Hoechst Aktiengesellschaft. His ingenuity and commitment to advancing medicinal solutions have earned him recognition among peers and within the broader scientific community.

Collaborations: Throughout his career, Becker has collaborated with notable colleagues, including Hansjorg Urbach and Rainer Henning. These partnerships have fostered an environment of innovation, leading to the development of groundbreaking medicinal compounds.

Conclusion: Reinhard Becker's dedication to innovation in medicinal chemistry is evident through his numerous patents and collaborative efforts. His work continues to contribute to the advancement of therapeutic solutions, solidifying his legacy as a key figure in his field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…